A Prospective, Open-Label, Observational, Multi-Center Study for the Identification of Predictive Factors for the Solifenacin Treatment in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks and Evaluation of Efficacy and Persistency of Add on Solifenacin in Men With Residual Overactive Bladder Symptoms After Previous Monotherapy With Tamsulosin.

Trial Profile

A Prospective, Open-Label, Observational, Multi-Center Study for the Identification of Predictive Factors for the Solifenacin Treatment in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks and Evaluation of Efficacy and Persistency of Add on Solifenacin in Men With Residual Overactive Bladder Symptoms After Previous Monotherapy With Tamsulosin.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Solifenacin (Primary) ; Tamsulosin
  • Indications Lower urinary tract symptoms; Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 11 Oct 2011 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
    • 11 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Apr 2010 Actual patient number (303) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top